Infection and Guillain-Barré syndrome

Infection and Autoimmunity, 2nd edition

Volumn , Issue , 2004, Pages 591-612

  van Sorge, N M ^a   van den Berg, Leonard H ^a   Jansen, M D ^a   van de Winkel, Jan G J ^a   van der Pol, W Ludo ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 49349100326     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-044451271-0.50046-6     Document Type: Chapter

References (209)

1. Ledeen RW, Yu RK Gangliosides: structure, isolation, and analysis. Methods Enzymol 1982, 83:139-191.
2. Svennerholm L Designation and schematic structure of gangliosides and allied glycosphingolipids. Prog Brain Res 1994, 101:XI-XIV.
3. Ogawa-Goto K, Funamoto N, et al. Myelin gangliosides of human peripheral nervous system: an enrichment of GM1 in the motor nerve myelin isolated from cauda equina. J Neurochem 1992, 59:1844-1849.
4. Gong Y, Tagawa Y, et al. Localization of major gangliosides in the PNS: implications for immune neuropathies. Brain 2002, 125:2491-2506.
5. Chiba A, Kusunoki S, et al. Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome. Brain Res 1997, 745:32-36.
6. Malisan F, Testi R GD3 ganglioside and apoptosis. Biochim Biophys Acta 2002, 1585:179-187.
7. Hakomori SI Cell adhesion/recognition and signal transduction through glycosphingolipid microdomain. Glycoconj J 2000, 17:143-151.
8. Vyas AA, Patel HV, et al. Ganglioisdes are functional nerve cell ligands for Myelin-associated glycoprotein (MAG), an inhibitor of nerve regeneration. Proc Natl Acad Sci USA 2002, 99:8412-8417.
9. Riggott MJ, Matthew WD Neurite outgrowth is enhanced by anti-idiotypic monoclonal antibodies to the ganglioside GM1. Exp Neurol 1997, 145:278-287.
10. Hakomori SI Inaugural Article: The glycosynapse. Proc Natl Acad Sci USA 2002, 99:225-232.
11. Ledeen RW, Wu G Ganglioside function in calcium homeostasis and signaling. Neurochem Res 2002, 637-647.
12. Kazarian T, Jabbar AA, et al. Gangliosides regulate tumor cell adhesion to collagen. Clin Exp Metastasis 2003, 20:311-319.
13. Saha S, Mohanty KC Correclation of gangliosides GM2 and GM3 with metastatis potential to lungs of mouse B16 melanoma. J Exp Clin Cancer Res 2003, 22:125-134.
14. Schengrund CL "Multivalent" saccharides: development of new approaches for inhibiting the effects of glycosphingolipid-binding pathogens. Biochem Pharmacol 2003, 65:699-707.
15. Sheikh KA, Sun J, et al. Mice lacking complex gangliosides develop Wallerian degeneration and myelination defects. Proc Natl Acad Sci USA 1999, 96:7532-7537.
16. Takamiya K, Yamamoto A, et al. Mice with disrupted GM2/GD2 synthase gene lack complex gangliosides but exhibit only subtle defects in their nervous system. Proc Natl Acad Sci USA 1996, 93:10662-10667.
17. Furukawa K, Takamiya K Beta 1,4-N-acetylgalactos-aminyltransferase-GM2/GD2 synthase: a key enzyme to control the synthesis of brain-enriched complex gangliosides. Biochim Biophys Acta 2002, 1573:356-362.
18. Chiavegatto S, Sun J, et al. A functional role for complex gangliosides: motor deficits in GM2/GD2 synthase knockout mice. Exp Neurol 2000, 166:227-234.
19. Kawai H, Allende ML, et al. Mice expressing only monosialoganglioside GM3 exhibit lethal audiogenic seizures. J Biol Chem 2001, 276:6885-6888.
20. Kasahara K, Watanabe Y, et al. Association of Src family tyrosine kinase Lyn with ganglioside GD3 in rat brain. Possible regulation of Lyn by glycosphingolipid in caveolae-like domains. J Biol Chem 1997, 272:29947-29953.
21. Miyakawa T, Yagi T, et al. Enhanced susceptibility of audiogenic seizures in Fyn-kinase deficient mice. Brain Res Mol Brain Res 1995, 28:349-352.
22. Fishman PH, Max SR, et al. Deficient Ganglioside Biosynthesis: a novel human sphingolipidosis. Science 1975, 187:68-70.
23. Max SR, Maclaren NK, et al. GM3 (hematoside) sphingolipodystrophy. N Engl J Med 1974, 291:929-931.
24. Myerowitz R Tay-Saschs disease-causing mutations and neurtral polymorphisms in the Hex A gene. Hum Mutat 1997, 9:195-208.
25. Paschke E, Milos I, et al. Mutation analyses in 17 patients with deficiency in acid beta-galactosidase: three novel point mutations and high correlation of mutation W273L with Morquio disease type B. Hum Genet 2001, 109:159-166.
26. Callahan JW Molecular basic of GM1 gangliosidosis and Morquio disease, type B. Structure-function studies of lysosomal beta-galactosidase and the nonolysosomal beta-galactosidase-like protein. Biochim Biophys Acta 1999, 1455:85-103.
27. Hughes RA, Rees JH Clinical and epidemiologic features of Guillain-Barre syndrome. J Infect Dis 1997, 176:S92-S98.
28. Hadden RD, Karch H, et al. Preceding infections, immune factors, and outcome in Guillain-Barre syndrome. Neurology 2001, 56:758-765.
29. Winer JB Guillain Barre syndrome. Mol Pathol 2001, 54:381-385.
30. Hahn AF Guillain-Barre syndrome. Lancet 1998, 352:635-641.
31. Hafer-Macko CE, Sheikh KA, et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 1996, 39:625-635.
32. Putzu GA, Figarella-Branger D, et al. Immunohistochemical localization of cytokines, C5b-9 and ICAM-1 in peripheral nerve of Guillain-Barre syndrome. J Neurol Sci 2000, 174:16-21.
33. Griffin JW, Li CY, et al. Pathology of the motor-sensory axonal Guillain-Barre syndrome. Ann Neurol 1996, 39:17-28.
34. Hafer-Macko C, Hsieh ST, et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol 1996, 40:635-644.
35. Yuki N, Yoshino H, et al. Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis. Neurology 1990, 40:1900-1902.
36. Jacobs BC, van Doorn PA, et al. Camplyobacter jejuni infections and anti-GM1 antibodies in Guillain-Barre syndrome. Ann Neurol 1996, 40:181-187.
37. Rees JH, Gregson NA, et al. Anti-ganglioside GM1 antibodies in Guillain-Barre syndrome and their relationship to Campylobacter jejuni infection. Ann Neurol 1995, 38:809-816.
38. Willison HJ, O'Hanlon GM The immunopathogenesis of Miller Fisher syndrome. J Neuroimmunol 1999, 100:3-12.
39. Chiba A, Kusunoki S, et al. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barre syndrome: clinical and immunohistochemical studies. Neurology 1993, 43:1911-1917.
40. van der Meche FG, Schmitz PI A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N Engl J Med 1992, 326:1123-1129.
41. Malik U, Oleksowicz L, et al. Intravenous gamma-globulin inhibits binding of anti-GM1 to its target antigen. Ann Neurol 1996, 39:136-139.
42. Jacobs BC, O'Hanlon GM, et al. Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. Brain 2003, 22:22.
43. Buchwald B, Ahangari R, et al. Differential blocking effects of the monoclonal anti-GQ1b IgM antibody and alpha-latrotoxin in the absence of complement at the mouse neuromuscular junction. Neurosci Lett 2002, 334:25-28.
44. Buchwald B, de Baets M, et al. Neonatal Guillain-Barre syndrome: blocking antibodies transmitted from mother to child. Neurology 1999, 53:1246-1253.
45. Kwa MS, van Schaik IN, et al. Investigation of serum response to PMP22, connexin 32 and P(0) in inflammatory neuropathies. J Neuroimmunol 2001, 116:220-225.
46. Willison HJ, Veitch J, et al. Inter-laboratory validation of an ELISA for the determination of serum anti-ganglioside antibodies. Eur J Neurol 1999, 6:71-77.
47. Ilyas AA, Quarles RH, et al. Monoclonal IgM in a patient with paraproteinemic polyneuropathy binds to gangliosides containing disialosyl groups. Ann Neurol 1985, 18:655-659.
48. Alaedini A, Green PH, et al. Ganglioside reactive anti-bodies in the neuropathy associated with celiac disease. J Neuroimmunol 2002, 127:145-148.
49. Chapman J, Sela BA, et al. Antibodies to ganglioside GM1 in patients with Alzheimer's disease. Neurosci Lett 1988, 86:235-240.
50. Willison HJ, Yuki N Peripheral neuropathies and antiglycolipid antibodies. Brain 2002, 125:2591-2625.
51. van den Berg LH, Marrink J, et al. Anti-GM1 antibodies in patients with Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 1992, 55:8-11.
52. Garcia Guijo C, Garcia-Merino A, et al. Presence and isotype of anti-ganglioside antibodies in healthy persons, motor neuron disease, peripheral neuropathy, and other diseases of the nervous system. J Neuroimmunol 1995, 56:27-33.
53. Portoukalian J Immunogenicity of glycolipids. Clin Rev Allergy Immunol 2000, 19:73-78.
54. Freimer ML, McIntosh K, et al. Gangliosides elicit a T-cell independent antibody response. J Autoimmun 1993, 6:281-289.
55. Livingston PO, Ritter G, et al. Antibody response after immunization with the gangliosides GM1, GM2, GM3, GD2 and GD3 in the mouse. Cancer Immunol Immunother 1989, 29:179-184.
56. Mizutamari RK, Wiegandt H, et al. Characterization of anti-ganglioside antibodies present in normal human plasma. J Neuroimmunol 1994, 50:215-220.
57. Mitzutamari RK, Kremer LJ, et al. Anti-GM1 ganglioside IgM-antibodies present in human plasma: affinity and biological activity changes in a patient with neuropathy. J Neurosci Res 1998, 51:237-242.
58. Ilyas AA, Chen ZW, et al. Immunoglobulin G subclass distribution of autoantibodies to gangliosides in patients with Guillain-Barre syndrome. Res Commun Mol Pathol Pharmacol 2001, 109:115-123.
59. Yuki N, Ichihashi Y, et al. Subclass of IgG antibody to GM1 epitope-bearing lipopolysaccharide of Campylobacter jejuni in patients with Guillain-Barre syndrome. J Neuroimmunol 1995, 60:161-164.
60. Koga M, Yuki N, et al. Subclass distribution and the secretory component of serum IgA anti-ganglioside antibodies in Guillain-Barre syndrome after Campylobacter jejuni enteritis. J Neuroimmunol 1999, 96:245-250.
61. Schwerer B, Neisser A, et al. Distinct immunoglobulin class and immunoglobulin G subclass patterns against ganglioside GQ1b in Miller Fisher syndrome following different types of infection. Infect Immun 1999, 67:2414-2420.
62. Koga M, Yuki N, et al. Closs association of IgA antiganglioside antibodies with antecedent Campylobacter jejuni infection in Guillain-Barre and Fisher's syndromes. J Neuroimmunol 1998, 81:138-143.
63. Koga M, Yuki N, et al. Anti-GM1 antibody IgG subclass: A clinical recovery predictor in Guillain-Barre syndrome. Neurology 2003, 60:1514-1518.
64. Illa I, Ortiz N, et al. Acute axonal Guillain-Barre syndrome with IgG antibodies angainst motor axons following parenteral gangliosides. Ann Neurol 1995, 38:218-224.
65. Ala TA, Perfetti PA, et al. Two cases of acute anti-GM1 antibody elevations in response to exogenous GM1 without neurological symptoms. J Neuroimmunol 1994, 53:109-113.
66. Govoni V, Granieri E, et al. Exogenous gangliosides and Guillain-Barre syndrome. An observational study in the local health district of Ferrara, Italy. Brain 1997, 120:1123-1130.
67. Raschetti R, Maggini M, et al. Gangliosides and Guillain-Barre syndrome. J Clin Epidemiol 1995, 48:1399-1405.
68. Chiba A, Kusunoki S, et al. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol 1992, 31:677-679.
69. Kuwabara S, Yuki N, et al. IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barre syndrome. Ann Neurol 1998, 44:202-208.
70. Pan CL, Yuki N, et al. Acute sensory ataxic neuropathy associated with monospectific anti-GD1b IgG antibody. Neurology 2001, 57:1316-1318.
71. Miyazaki T, Kusunoki S, et al. Guillain-Barre syndrome associated with IgG monospectific to ganglioside GD1b. Neurology 2001, 56:1227-1229.
72. Susuki K, Yuki N, et al. Features of sensory ataxic neuropathy associated with anti-GD1b IgM antibody. J Neuroimmunol 2001, 112:181-187.
73. Ogawa-Goto K, Funamoto N, et al. Different ceramide compositions of gangliosides between human motor and sensory nerves. J Neurochem 1990, 55:1486-1493.
74. Kusunoki S, Hitoshi S, et al. Monospecific anti-GD1b IgG is required to induce rabbit ataxic neuropathy. Ann Neurol 1999, 45:400-403.
75. Kusunoki S, Shimizu J, et al. Experimental sensory neuropathy induced by sensitization with ganglioside GD1b. Ann Neurol 1996, 39:424-431.
76. Kusunoki S, Hitoshi S, et al. Degeneration of rabbit sensory neurons induced by passive transfer of anti-GD1b antiserum. Neurosci Lett 1999, 273:33-36.
77. Yuki N, Yamada M, et al. Animal model of axonal Guillain-Barre syndrome induced by sensitization with GM1 ganglioside. Ann Neurol 2001, 49:712-720.
78. Susuki K, Nishimoto Y, et al. Acute motor axonal neuropathy rabbit model: Immune attack on nerve root axons. Ann Neurol 2003, 54:383-388.
79. Toyka KV, Zielasek J, et al. Myelin-derived glycolipids and animal models of Guillain-Barre syndrome. Ann Neurol 2002, 51:532. discussion 532-3.
80. Ravichandra B, Joshi PG Regulation of transmembrane signaling by ganglioside GM1:interaction of anti-GM1 with Neuro2a cells. J Neurochem 1999, 73:557-567.
81. Quattrini A, Lorenzetti I, et al. Human IgM anti-GM1 autoantibodies modulate intracellular calcium homeostasis in neuroblastoma cells. J Neuroimmunol 2001, 114:213-219.
82. Bullens RW, O'Hanlon GM, et al. Complex gangliosides at the neuromuscular junction are membrane receptors for autoantibodies and botulinum neurotoxin but redundant for normal synaptic function. J Neurosci 2002, 22:6876-6884.
83. Buchwald B, Toyka KV, et al. Neuromuscular blockade by IgG antibodies from patients with Guillain-Barre syndrome: a macro-patch-clamp study. Ann Neurol 1998, 44:913-922.
84. Goodyear CS, O'Hanlon GM, et al. Monoclonal antibodies raised against Guillain-Barre syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations. J Clin Invest 1999, 104:697-708.
85. Buchwald B, Bufler J, et al. Combined pre- and post-synaptic action of IgG antibodies in Miller Fisher syndrome. Neurology 2001, 56:67-74.
86. Cavanna B, Jiang H, et al. Anti-GM(2) IgM antibody-induced complement-mediated cytotoxicity in patients with dysimmune neuropathies. J Neuroimmunol 2001, 114:226-231.
87. Koski CL Complement-fixing antiperipheral myelin antibodies and C9 neoantigen in serum of patients with Guillain-Barre syndrome: quantitation, kinetics, and clinical correlation. Ann NY Acad Sci 1987, 505:319-325.
88. Sawant-Mane S, Estep A, et al. Antibody of patients with Guillain-Barre syndrome mediates complement-dependent cytolysis of rat Schwann cells: susceptibility to cytolysis reflects Schwann cell phenotype. J Neuroimmunol 1994, 49:145-152.
89. Vriesendorp FJ, Flynn RE, et al. Complement depletion affects demyelination and inflammation in experimental allergic neuritis. J Neuroimmunol 1995, 58:157-165.
90. Vriesendorp FJ, Flynn RE, et al. Systemic complement depletion reduces inflammation and demyelination in adoptive transfer experimental allergic neuritis. Acta Neuropathol (Berl) 1998, 95:297-301.
91. Feasby TE, Gilbert JJ, et al. Complement depletion suppresses Lewis rat experimental allergic neuritis. Brain Res 1987, 419:97-103.
92. Vriesendorp FJ, Flynn RE, et al. Soluble complement receptor 1 (sCR1) is not as effective as cobra venom factor in the treatment of experimental allergic neuritis. Int J Neurosci 1997, 92:287-298.
93. Jung S, Toyka KV, et al. Soluble complement receptor type 1 inhibits experimental autoimmune neuritis in Lewis rats. Neurosci Lett 1995, 200:167-170.
94. Vedeler CA, Conti G, et al. The expression of CD59 in experimental allergic neuritis. J Neurol Sci 1999, 165:154-159.
95. Singhrao SK, Neal JW, et al. Spontaneous classical pathway activation and deficiency of membrane regulators render human neurons susceptible to complement lysis. Am J Pathol 2000, 157:905-918.
96. van der Pol W, van de Winkel JG IgG receptor polymorphisms: risk factors for disease. Immunogenetics 1998, 48:222-232.
97. Van Sorge NM, Van Der Pol WL, et al. FcgammaR polymorphisms: Implications for function, disease susceptibility and immunotherapy. Tissue Antigens 2003, 61:189-202.
98. van Egmond M, Damen CA, et al. IgA and the IgA Fc receptor. Trends Immunol 2001, 22:205-211.
99. Vedeler CA, Matre R, et al. Class and IgG subclass distribution of antibodies against peripheral nerve myelin in sera from patients with inflammatory demyelinating polyradiculoneuropathy. Acta Neurol Scand 1988, 78:401-407.
100. Ogino M, Orazio N, et al. IgG anti-GM1 antibodies from patients with acute motor neuropathy are predominantly of the IgG1 and IgG3 subclasses. J Neuroimmunol 1995, 58:77-80.
101. Van Sorge NM, Van Den Berg LH, et al. Anti-GM1 IgG antibodies induce leukocyte effector functions via Fcgamma receptors. Ann Neurol 2003, 53:570-579.
102. Lopez PH, Villa AM, et al. High affinity as a disease determinant factor in anti-GM(1) antibodies: comparative characterization of experimentally induced vs. disease-associated antibodies. J Neuroimmunol 2002, 128:69-76.
103. Tagawa Y, Laroy W, et al. Anti-ganglioside antibodies bind with enhanced affinity to gangliosides containing very long chain fatty acids. Neurochem Res 2002, 27:847-855.
104. Itonori S, Hidari K, et al. Involvement of the acyl chain of ceramide in carbohydrate recognition by an anti-glycolipid monoclonal antibody: the case of an anti-melanoma antibody, M2590, to GM3-ganglioside. Glycoconj J 1989, 6:551-560.
105. Kusunoki S, Morita D, et al. Binding of immunoglobulin G antibodies in Guillain-Barre syndrome sera to a mixture of GM1 and a phospholipid: possible clinical implications. Muscle Nerve 2003, 27:302-306.
106. Ogawa-Goto K, Abe T Gangliosides and glycosphin-golipids of peripheral nervous system myelins-a minireview. Neurochem Res 1998, 23:305-310.
107. Jacobs BC, Rothbarth PH, et al. The spectrum of antecedent infections in Guillain-Barre syndrome: a case-control study. Neurology 1998, 51:1110-1115.
108. Mori M, Kuwabara S, et al. Haemophilus influenzae infection and Guillain-Barre syndrome. Brain 2000, 123:2171-2178.
109. Koga M, Yuki N, et al. Miller Fisher syndrome and Haemophilus influenzae infection. Neurology 2001, 57:686-691.
110. Hao Q, Saida T, et al. Antibodies to gangliosides and galactocerebroside in patients with Guillain-Barre syndrome with preceding Campylobacter jejuni and other identified infections. J Neuroimmunol 1998, 81:116-126.
111. Brandtzaeg P Humoral immune response patterns of human mucosae: induction and relation to bacterial respiratory tract infections. J Infect Dis 1992, 165:S167-S176.
112. Wassenaar TM Toxin production by Campylobacter spp. Clin Microbiol Rev 1997, 10:466-476.
113. Ruiz-Palacios GM, Torres J, et al. Cholera-like enterotoxin produced by Campylobacter jejuni. Characterisation and clinical significance. Lancet 1983, 2:250-253.
114. Wassenaar TM, Blaser MJ Pathophysiology of Campylobacter jejuni infections of humans. Microbes Infect 1999, 1:1023-1033.
115. Yuki N, Taki T, et al. A bacterium lipopolysaccharide that elicits Guillain-Barre syndrome has a GM1 ganglioside-like structure. J Exp Med 1993, 178:1771-1775.
116. Penner JL, Aspinall GO Diversity of lipopolysaccharide structures in Campylobacter jejuni. J Infect Dis 1997, 176:S135-S138.
117. Jacobs BC, Endtz HP, et al. Humoral immune response against Campylobacter jejuni lipopolysaccharides in Guillain-Barre and Miller Fisher syndrome. J Neuroimmunol 1997, 79:62-68.
118. Gregson NA, Rees JH, et al. Reactivity of serum IgG anti-GM1 ganglioside antibodies with the lipopolysaccharide fractions of Campylobacter jejuni isolates from patients with Guillain-Barre syndrome (GBS). J Neuroimmunol 1997, 73:28-36.
119. Ang CW, Laman JD, et al. Structure of Campylobacter jejuni lipopolysaccharides determines antiganglioside specificity and clinical features of Guillain-Barre and Miller Fisher patients. Infect Immun 2002, 70:1202-1208.
120. Kopecko DJ, Hu L, et al. Campylobacter jejuni-microtubule-dependent invasion. Trends Microbiol 2001, 9:389-396.
121. Kiehlbauch JA, Albach RA, et al. Phagocytosis of Campylobacter jejuni and its intracellular survival in mononuclear phagocytes. Infect Immun 1985, 48:446-451.
122. Wassenaar TM, Engelskirchen M, et al. Differential uptake and killing potential of Campylobacter jejuni by human peripheral monocytes/macrophages. Med Microbiol Immunol (Berl) 1997, 186:139-144.
123. Van Rhijn I, Bleumink-Pluym NM, et al. Campylobacter DNA is present in circulating myelomonocytic cells of healthy persons and in persons with Guillain-Barre syndrome. J Infect Dis 2002, 185:262-265.
124. Van Rhijn I, Van den Berg LH, et al. Expansion of human gammadelta T cells after in vitro stimulation with Campylobacter jejuni. Int Immunol 2003, 15:373-382.
125. Wiertz EJ, Mukherjee S, et al. Viruses use stealth technology to escape from the host immune system. Mol Med Today 1997, 3:116-123.
126. Jones TR, Wiertz EJ, et al. Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains. Proc Natl Acad Sci USA 1996, 93:11327-11333.
127. Wiertz EJ, Jones TR, et al. The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell 1996, 84:769-779.
128. MacCormac LP, Grundy JE Human cytomegalovirus induces an Fc gamma receptor (Fc gammaR) in endothelial cells and fibroblasts that is distinct from the human cellular Fc gammaRs. J Infect Dis 1996, 174:1151-1161.
129. Ang CW, Jacobs BC, et al. Cross-reactive antibodies aginst GM2 and CMV-infected fibroblasts in Guillain-Barre syndrome. Neurology 2000, 54:1453-1458.
130. Jacobs BC, van Doorn PA, et al. Cytomegalovirus infections and anti-GM2 antibodies in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 1997, 62:641-643.
131. Irie S, Saito T, et al. Association of anti-GM2 antibodies in Guillain-Barre syndrome with acute cytomegalovirus infection. J Neuroimmunol 1996, 68:19-26.
132. Yuki N, Tagawa Y Acute cytomegalovirus infection and IgM anti-GM2 antibody. J Neurol Sci 1998, 154:14-17.
133. Tanner J, Weis J, et al. Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. Cell 1987, 50:203-213.
134. Li Q, Turk SM, et al. The Epstein-Barr virus (EBV) BZLF2 gene product associates with the gH and gL homologs of EBV and carries an epitope critical to infection of B cells but not of epithelial cells. J Virol 1995, 69:3987-3994.
135. Spriggs MK, Armitage RJ, et al. The extracellular domain of the Epstein-Barr virus BZLF2 protein binds the HLA-DR beta chain and inhibits antigen presentation. J Virol 1996, 70:5557-5563.
136. Nakagomi H, Dolcetti R, et al. The Epstein-Barr virus latent membrane protein-1 (LMP1) induces interleukin-10 production in Burkitt lymphoma lines. Int J Cancer 1994, 57:240-244.
137. Burkhardt AL, Bolen JB, et al. An Epstein-Barr virus transformation-associated membrane protein interacts with src family tyrosine kinases. J Virol 1992, 66:5161-5167.
138. Moore KW, Vieira P, et al. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science 1990, 248:1230-1234.
139. Kusunoki S, Chiba A, et al. Anti-Gal-C antibody in autoimmune neuropathies subsequent to mycoplasma infection. Muscle Nerve 1995, 18:409-413.
140. Ang CW, Tio-Gillen AP, et al. Cross-reactive anti-galactocerebroside antibodies and Mycoplasma pneumoniae infections in Guillain-Barre syndrome. J Neuroimmunol 2002, 130:179-183.
141. Saida T, Saida K, et al. Experimental allergic neuritis induced by sensitization with galactocerebroside. Science 1979, 204:1103-1106.
142. Olson JK, Croxford JL, et al. A virus-induced molecular mimicry model of multiple sclerosis. J Clin Invest 2001, 108:311-318.
143. Penner JL, Hennessy JN Passive hemagglutination technique for serotyping Campylobacter fetus subsp. jejuni on the basis of soluble heat-stable antigens. J Clin Microbiol 1980, 12:732-737.
144. Karlyshev AV, Linton D, et al. Genetic and biochemical evidence of a Campylobacter jejuni capsular polysaccharide that accounts for Penner serotype specificity. Mol Microbiol 2000, 35:529-541.
145. Allos BM, Lippy FT, et al. Campylobacter jejuni strains from patients with Guillain-Barre syndrome. Emerg Infect Dis 1998, 4:263-268.
146. Fujimoto S, Yuki N, et al. Specific serotype of Campylobacter jejuni associated with Guillain-Barre syndrome. J Infect Dis 1992, 165:183.
147. Kuroki S, Saida T, et al. Campylobacter jejuni strains from patients with Guillain-Barre syndrome belong mostly to Penner serogroup 19 and contain beta-N-acetylglucosamine residues. Ann Neurol 1993, 33:243-247.
148. Lastovica AJ, Goddard EA, et al. Guillain-Barre syndrome in South Africa associated with Campylobacter jejuni O:41 strains. J Infect Dis 1997, 176:S139-S143.
149. Engberg J, Nachamkin I, et al. Absence of clonality of Campylobacter jejuni in serotypes other than HS:19 associated with Guillain-Barre syndrome and gastroenteritis. J Infect Dis 2001, 184:215-220.
150. Endtz HP, Ang CW, et al. Molecular characterization of Campylobacter jejuni from patients with Guillain-Barre and Miller Fisher syndromes. J Clin Microbiol 2000, 38:2297-2301.
151. Nachamkin I, Engberg J, et al. Molecular population genetic analysis of Campylobacter jejuni HS:19 associated with Guillain-Barre syndrome and gastroenteritis. J Infect Dis 2001, 184:221-226.
152. Wassenaar TM, Fry BN, et al. Genetic characterization of Campylobacter jejuni O:41 isolates in relation with Guillain-Barre syndrome. J Clin Microbiol 2000, 38:874-876.
153. Fujimoto S, Allos BM, et al. Restriction fragment length polymorphism analysis and random amplified polymorphic DNA analysis of Campylobacter jejuni strains isolated from patients with Guillain-Barre syndrome. J Infect Dis 1997, 176:1105-1108.
154. Dingle KE, Van Den Braak N, et al. Sequence typing confirms that Campylobacter jejuni strains associated with Guillain-Barre and Miller-Fisher syndromes are of diverse genetic lineage, serotype, and flagella type. J Clin Microbiol 2001, 39:3346-3349.
155. van Belkum A, van den Braak N, et al. A Campylobacter jejuni gene associated with immune-mediated neuropathy. Nat Med 2001, 7:752-753.
156. Blaser MJ Epidemiologic and clinical features of Campylobacter jejuni infections. J Infect Dis 1997, 176(Suppl 2):S103-S105.
157. Allos BM Association between Campylobacter infection and Guillain-Barre syndrome. J Infect Dis 1997, 176:S125-S128.
158. Wilmshurst JM, Pohl KR, et al. Familial Guillain-Barre syndrome. Eur J Neurol 1999, 6:499-503.
159. Ang CW, van Doorn PA, et al. A case of Guillain-Barre syndrome following a family outbreak of Campylobacter jejuni enteritis. J Neuroimmunol 2000, 111:229-233.
160. Westendorp RG, Langermans JA, et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997, 349:170-173.
161. Hohnoki K, Inoue A, et al. Elevated serum levels of IFN-gamma, IL-4 and TNF-alpha/unelevated serum levels of IL-10 in patients with demyelinating diseases during the acute stage. J Neuroimmunol 1998, 87:27-32.
162. Creange A, Belec L, et al. Circulating tumor necrosis factor (TNF)-alpha and soluble TNF-alpha receptors in patients with Guillain-Barre syndrome. J Neuroimmunol 1996, 68:95-99.
163. Exley AR, Smith N, et al. Tumour necrosis factor-alpha and other cytokines in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 1994, 57:1118-1120.
164. Ma JJ, Nishimura M, et al. Genetic contribution of the tumor necrosis factor region in Guillain-Barre syndrome. Ann Neurol 1998, 44:815-818.
165. de Jong BA, Westendorp RG, et al. Polymorphisms in or near tumour necrosis factor (TNF)-gene do not determine levels of endotoxin-induced TNF production. Genes Immun 2002, 3:25-29.
166. Hillert J, Osterman PO, et al. No association with HLA-DR, -DQ or -DP alleles in Guillain-Barre syndrome. J Neuroimmunol 1991, 31:67-72.
167. Li H, Yuan J, et al. HLA alleles in patients with Guillain-Barre syndrome. Chin Med J (Engll) 2000, 113:429-432.
168. Ma JJ, Nishimura M, et al. HLA and T-cell receptor gene polymorphisms in Guillain-Barre syndrome. Neurology 1998, 51:379-384.
169. Magira EE, Papaioakim M, et al. Differential distribution of HLA-DQ beta/DR beta epitopes in the two forms of Guillain-Barre syndrome, acute motor axonal neuropathy and acute inflammatory demyelinating polyneuropathy (AIDP): identification of DQ beta epitopes associated with susceptibility to and protection from AIDP. J Immunol 2003, 170:3074-3080.
170. Chiba A, Kusunoki S, et al. HLA and anti-GQ1b IgG antibody in Miller Fisher syndrome and Guillain-Barre syndrome. J Neuroimmunol 1995, 61:85-88.
171. Winer JB, Briggs D, et al. HLA antigens in the Guillain-Barre syndrome. J Neuroimmunol 1988, 18:13-16.
172. Monos DS, Papaioakim M, et al. Differential distribution of HLA alleles in two forms of Guillain-Barre syndrome. J Infect Dis 1997, 176:S180-S182.
173. Rees JH, Vaughan RW, et al. HLA-class II alleles in Guillain-Barre syndrome and Miller Fisher syndrome and their association with preceding Campylobacter jejuni infection. J Neuroimmunol 1995, 62:53-57.
174. Ravetch JV, Bolland S IgG Fc receptors. Annu Rev Immunol 2001, 19:275-290.
175. van der Pol WL, van den Berg LH, et al. IgG receptor IIa alleles determine susceptibility and severity of Guillain-Barre syndrome. Neurology 2000, 54:1661-1665.
176. Vedeler CA, Raknes G, et al. IgG Fc-receptor polymorphisms in Guillain-Barre syndrome. Neurology 2000, 55:705-707.
177. Hartung HP, Reiners K, et al. Serum interleukin-2 concentrations in Guillain-Barre syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: comparison with other neurological diseases of pre sumed immunopathogenesis. Ann Neurol 1991, 30:48-53.
178. Hartung HP, Hughes RA, et al. T cell activation in Guillain-Barre syndrome and in MS: elevated serum levels of soluble IL-2 receptors. Neurology 1990, 40:215-218.
179. Koga M, Yuki N, et al. CDR3 spectratyping analysis of the T cell receptor repertoire in Guillain-Barre and Fisher syndromes. J Neuroimmunol 2003, 141:112-127.
180. Wanschitz J, Maier H, et al. Distinct time pattern of complement activation and cytotoxic T cell response in Guillain-Barre syndrome. Brain 2003, 126:2034-2042.
181. Shamshiev A, Donda A, et al. Self glycolipids as T-cell autoantigens. Eur J Immunol 1999, 29:1667-1675.
182. Matsuda JL, Kronenberg M Presentation of self and microbial lipids by CD1 molecules. Curr Opin Immunol 2001, 13:19-25.
183. Jayawardena-Wolf J, Bendelac A CD1 and lipid antigens: intracellular pathways for antigen presentation. Curr Opin Immunol 2001, 13:109-113.
184. Shamshiev A, Donda A, et al. The alphabeta T cell response to self-glycolipids shows a novel mechanism of CD 1b loading and a requirement for complex oligosaccharides. Immunity 2000, 13:255-264.
185. Shamshiev A, Gober HJ, et al. Presentation of the same glycolipid by different CD1 molecules. J Exp Med 2002, 195:1013-1021.
186. Joyce S, Van Kaer L CD1-restricted antigen presentation: an oily matter. Curr Opin Immunol 2003, 15:95-104.
187. Cooper JC, Hughes S, et al. T cell recognition of a nonprotein antigen preparation of Campylobacter jejuni in patients with Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 2002, 72:413-414.
188. Khalili-Shirazi A, Gregson NA, et al. The distribution of CD1 molecules in inflammatory neuropathy. J Neurol Sci 1998, 158:154-163.
189. Nieuwenhuis EE, Visser MR, et al. Oral antibiotics as a novel therapy for arthritis: evidence for a beneficial effect of intestinal Escherichia coli. Arthritis Rheum 2000, 43:2583-2589.
190. Maloy KJ, Salaun L, et al. CD4+CD25+T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms. J Exp Med 2003, 197:111-119.
191. Pasare C, Medzhitov R Toll pathway-dependent blockade of CD4+CD25+T cell-mediated suppression by dendritic cells. Science 2003, 299:1033-1036.
192. Martin F, Kearney JF B1 cells: similarities and differences with other B cell subsets. Curr Opin Immunol 2001, 13:195-201.
193. Murakami M, Honjo T Involvement of B-1 cells in mucosal immunity and autoimmunity. Immunol Today 1995, 16:534-539.
194. Macpherson AJ, Gatto D, et al. A primitive T cell-independent mechanism of intestinal mucosal IgA responses to commensal bacteria. Science 2000, 288:2222-2226.
195. Fagarasan S, Honjo T T-Independent immune response: new aspects of B cell biology. Science 2000, 290:89-92.
196. Zandvoort A, Timens W The dual function of the splenic marginal zone: essential for initiation of anti-TI-2 responses but also vital in the general first-line defense against blood-borne antigens. Clin Exp Immunol 2002, 130:4-11.
197. Guinamard R, Okigaki M, et al. Absence of marginal zone B cells in Pyk-2-deficient mice defines their role in the humoral response. Nat Immunol 2000, 1:31-36.
198. Llorente L, Richaud-Patin Y, et al. Dysregulation of interleukin-10 production in relatives of patients with systemic lupus erythematosus. Arthritis Rheum 1997, 40:1429-1435.
199. Torres BA, Perrin GQ, et al. Superantigen enhancement of specific immunity: antibody production and signaling pathways. J Immunol 2002, 169:2907-2914.
200. Silverman GJ B-cell superantigens. Immunol Today 1997, 18:379-386.
201. Khalili-Shirazi A, Gregson NA, et al. T cell receptor V beta gene usage in Guillain-Barre syndrome. J Neurol Sci 1997, 145:169-176.
202. Leadbetter EA, Rifkin IR, et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002, 416:603-607.
203. Dempsey PW, Allison ME, et al. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 1996, 271:348-350.
204. Sato S CD19 is a central response regulator of B lymphocyte signaling thresholds governing autoimmunity. J Dermatol Sci 1999, 22:1-10.
205. Sato S, Hasegawa M, et al. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 2000, 165:6635-6643.
206. Balazs M, Martin F, et al. Blood dendritic cells interact with splenic marginal zone B cells to initiate T-independent immune responses. Immunity 2002, 17:341-352.
207. Groom J, Kalled SL, et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest 2002, 109:59-68.
208. Zhang J, Roschke V, et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001, 166:6-10.
209. Phan TG, Amesbury M, et al. B cell receptor-independent stimuli trigger immunoglobulin (Ig) class switch recombination and production of IgG autoantibodies by anergic self-reactive B cells. J Exp Med 2003, 197:845-860.